Литературный обзор курсовой работы студентки 4-го курса кафедры высшей нервной деятельности Биологического факультета МГУ. Москва, 2001
Авторские права сохранены. Любое копирование данного текста и/или его фрагментов без разрешения автора  запрещено и преследуется в соответствии с действующим законодательством РФ.

Содержание   В начало...
 
 

1. Ашмарин и др. Биохимия мозга: учебное пособие. СПб: Издательство С.-Петербургского университета, 1999.

2. Арушанян Э.Б., Отеллин В.А. Хвостатое ядро. Л.:Наука, 1976

3. Глебов Р. Н., Крыжановский Г. Н. Функциональная биохимия синапсов. М. : Медицина, 1978, 221-261.

4. Машковский М. Д., Андреева Н. И., Полежаева А. Н. Фармакология антидепрессантов. М.: Медицина, 1983

5. Мухин Е. И. Структурные, функциональные и нейрохимические основы сложных форм поведения. М: Медицина, 1990.

6. Раевский К. С. Функциональная роль и фармакологическая регуляция дофаминергической системы мозга. Вестник РАМНб 1998,8б стр.19-24.

7. Саульская Н.Б. Объемная передача как способ межнейронального взаимодествия в стриатуме. Журнал ВНД., 1997т.47, вып 2:362.,

8. Сергеев П. В., Шимановский Н. Л., Петров В. И. Рецепторы физиологически активных веществ: монография. - Волгоград..-Семь ветров.- 1999.

9. Харкевич Д. А. Фармакология: Учебник., 6-е изд., М.: ГЭОТАР Медицина, 2000.

10. Ahlander, M., Misane, I., Schott, P.A., and Ogren, S.O. A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology, 1999, 21:414-426.

11. Arbuthoutt G. W., Fairbrother I.S., Butcher S. P., Brain microdialysis studies on control of dopamine release and metabolism in vivo., J. of Neurosci. Meth., 1990, Vol. 649., P.73-81.

12. BENINGER, R. J.,D. C. HOFFMAN,and E. J. MAZURSKI.Receptor subtype-specific dopaminergic agents and conditioned behavior. Neurosci. Biobehav. Rev., 1989, Vol.13: 113-122, 1989.

13. Berridge K. C. and Robinson T. E. What is the role of dopamine in reward:hedonic impact, reward learning, or incentive salience? , Brain. Res. Rev.,1998, Vol 28:3:309-369.

14. Bjorklund A., Lindvall O. Dopamine-containing systems in the CNS//Dook of chemical neuroanatomy. Classical transmitters in the cat.-1984.-Vol.2.-P.55-122.

15. Bristow L. J., Thorn L., Tricklebank M. D., Hutson P. H. Competitive NMDA receptor antagonists attenuate the behavioral and neurochemical effects of amphetamine in mice., Eur. J. Pharmacol., 1994, Vol 264(3):353-9.

16. Cawthon R. M. and Breakfield X.O. Differences A and B forms of monoamineoxidase revealed by limited proteolysis and peptide mapping. Nature, 1979, Vol. 281, P. :692-694.

17. Clements J. D., Lester R. A. J., Tong G., Jahr C. E., Westbrook G. L. The timecourse of glutamate in the synaptic cleft. science, 1992, Vol.258, P.:1498-1501.

18. Clow D. W., Jhamandask A. Characterization of L-glutamate action on the release of endogenous dopamine from hevrat caudate-putamen. J. Pharm. Exp. Ther., 1989, Vol.248, P.:722-728 .

19. Cole S. O. Brain mechanisms of amphetamine-induced anorexia, locomotion and stereotypy. Neurosci. Biobehav. Rev., 1978, Vol 2(2), P. :89-100.

20. Danysz W., Essman U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats., Pharmacol. Biochem. Behav., 1994, Vol. 48, P.:1111-8.

21. Danysz W., Parsons C., Kornhuber J., Schmidt W., Quack G. Aminoadamantanes as NMDA receptor anatagonists and antiparkinsonian agents - preclinical studies. Neurosci. and Biobeh. Rev., 1997, Vol. 21(4), P.:455-468.

22. Di Chiara G., Morelli M., Consolo S. Modulatory function of neurotransmitters in the striatun: Ach/dopamine/NMDA interactions. Trends Neurosci., 1994, Vol.17,228-233.

Fink J. S.and Smith G.P., Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats., Brain Res., 1980 Oct 20, 199:2359-84

23. Fisher A., Starr M. S. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Brain. Res., 2000, Vol. 868(2), P. :268-274.

24. Giuffra M.E., Sethy V.H., Davis T.L., Mouradian M.M., Chase T.N. Milacemide therapy for parkinson's desease.., Mov. Disord., 1993, Vol. 8, P.:147-50.

25. Gorter J. A., de Bruin J. P. Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat. Brain. Res., 1992 May 15, Vol. 580:1-212-7

26. Ikemoto S.and Panksepp J., The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special interference to reward -seeking., Brain Res. Rev., 1999, Vol.31, 1, P.6-41.

27. Jin S. AMPA- and kainite-receptors differentially mediate excitatory aminoacid-induced dopamine and acetylcholine release from rat striatal slices. Neuropharmacology, 1997, 36, P.:1503-1510.

28. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neuroscience, 1998, 18(6):1979-86.

29. Karler R., Calder L. D., Thai L. H., Bedingfield J. B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine. Brain. Res., 1994, Vol. 658(1-2), P. :8-14.

30. Kaur S, Starr MS Differential effects of intrastriatal and intranigral injections of glutamate anatagonists on motor behaviour in the reserpine-treated rats. Neuroscience 1997, 76(2):345-54

31. Kotter R., Postsynaptic integration of glutamatergic and dopaminergic signals in striatum., Prog. Neurobiol.,1994, Vol. 44:2163-96.

32. MALDONADO, R.,P. ROBLEDO,A. J. CHOVER,S. B. CAINE,and G. F. KOOB.D1 dopamine receptors in the nucleus accumbens modulate cocaine self-administration in the rat. Pharmacol. Biochem. Behav., 1993, 45: 239-242.

33. Lassen J. The effect of amantadine and (+) amphetamine on motility in rats after inhibition of monoamine synthesis and storage. Psychopharmacologia, 1973, Vol.29, P.:55-64.

34. LEVIN, E. D.,and J. E. ROSE. Acute and chronic nicotinic interaction with dopamine systems and working memory performance. Ann. NY Acad. Sci.,1995, 757: 245-252,

35. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neurosciense, 1999, Vol.88: 11-16

36. Mizoguchi K., Yokoo H., Yoshida M., Tanako T., Tanaka M. Amantadine increases extracellular dopamine levels in striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res., 1994, Vol. 662, P. :255-258.

37. Missale C., Nash S. R., Robinson S. W., Jaber M., Caron M. G. Dopamine receptors: from structure to function. Physiol. Rev., 1998, Vol. 78, P.:1189-225.

38. Moghaddam B. And Bolinao M. L., Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse, 1994, Vol. 18 P.:4337-42.

39. Ozawa S., Kamiya H., Tsuzuki K., Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol., 1998, Vol. 54, P. :581-618.

40. PACKARD, M. G.and N. M. WHITE. Dissociation of hippocampus and caudate nucleus memory systems by post-training intracerebral injection of dopamine agonists.Behav. Neurosci., 1991, Vol.105: 295-306, 1991

41. Page G., Peeters M., Maloteaux J-M., Hermans E. Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine. European Journal of Pharmacology, 2000, Vol.403:1-2:75-80.

42. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drugs New Perspect ,1998, 11(9),

43. Parsons C.G., Quack G., Bresink I., Baran L. et al., Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology, 1995 Oct, Vol. 34, P.:101239-58.

44. PHILLIPS, G. D.,T. W. ROBBINS and B. J. EVERITT.Bilateral intra-accumbens self-administration of d-amphetamine: antagonism with intra-accumbens SCH 23390 and sulpiride. Psychopharmacology, 1994 114: 477-485,

45. Quack G., Hesselink M., Danysz W., Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J. of Neural Transmission, 1995, Vol.46(Suppl.), P.:95-102.

46. Prepas S., Menon M. K., Clark W. G. Blockade of the central effects of d-amphetamine by amantadine. Arzneimittelforschung, 1975, Vol. 25, P. :5780-2

47. Randrup A., Munkvad J., Pharmacology and physiology of stereotypal behavior. J. Psychiat. Res., 1974, Vol.11, P.:1-10

48. Seeman P. Brain dopamine receptors. Pharmacol. Rev. ,1980, Vol. 32, P. 229-331.

49. Seeman P.and Van Tol H. M. Dopamine receptor pharmacology., Trends Pharmacol. Sci., 1983

50. SELF, D. W., BARNHART W. J.,. LEHMAN D. A,and NESTLER E. J..Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine eceptor agonists. Science, 1996,271: 1586-1589.

51. Schultz W., Apicella P, Ljungberg T. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task.J. Neurosci., 1993, 13: 900-913.

52. Sharp T., Zetterstrom T., Ljunberg T., Ungerstedt U. Effect of sulpiride on aphetamine-induced behavior in relation to changes in striatal dopamine release in vivo. Eur. J. Pharmacol., 1986 Vol. 129, P.:411-5.

53. Sonsalla P. K., Gibb J., Hanson G.R. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine system. J. Pharmacol. Exp. Ther., 1986, Vol.238, P.:932-937.

54. Sonsalla P. K., Riordan D. E., Heikkila R. E. Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice., J. Pharmacol. Exp. Ther., 1991 Feb, Vol. 256, P.:2506-12

55. Spanagel R., Eilbacher B., Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmacokinetic microdialysis study. Eur. J. of Pharm., 1994, Vol 262, P. :21-26)

56. St-Pierre J.A., Bedard PJ. Intranigral but not intrastriatal microinjection of NMDA antagonists MK-801 induces contralateral circling in the 6-OHDA rat model. Brain Res 1994, Vol. 17, 660:2255-60

57. Starr MS, Antiparkinsonian actions of glutamate antagonists - alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms., J.Neural. Transm. Park. Dis. Dement. sect 1995, 10:2-3141-85

58. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine., J. Neurosci. Res., 1999 Mar 15; 55(6): 659-65

59. Sulzer D., Rayport S. Amphetamines and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules. A mechanism of action. Neuron,1990, Vol.5, P.:797-808.

60. Tarazi F. I., Campbell A., Yeghiayan S. K., Baldessarini R. J.. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. Synapse, 1998, Vol. 30(2), P. : 227-35.

61. Tzschentke T. M., Phatmacology and behavioral pharmacology of the mesocortical dopamine system., Prog. In Neurobiology., 2001, 63, P.241-320

62. Uitti R. J., Rajput A. H., Ahlskog J. E., Offord K. P. et al.. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology, 1996, Vol.46(6), P. : 1551-6.

63. Ulas J., Wiehmuller F. B., Brunner l. C., Joyce J. N., Marshall J., Colman C. W. selective increase of NMDA-selective glutamate binding in the striatum of Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J. of Neurosci., 1994, Vol. 14, P.:6317-6324.

64. Uzbay T., Wallis C. J., Harbans L., Foster M. Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice. Beh. Brain. Res.,1999, Vol. 108(1), P. :57-61.

65. Wedzony

66. Weihmuller F. B., O'Dell S.J., Marshall S. J. MK-801 protects against methamphetamine -induced striatal dopamine terminal injury as associated with attenuated dopamine overflow. Synapse, 1992, Vol. 11: 155-63.

67. White, N. M.,Packard M.G., and Seamans J..Memory enhancement by post-training peripheral administration of low doses of dopamine agonists: possible autoreceptor effect. Behav. Neural Biol. , 1993 59: 230-241 .

68. White, N. M.,and M. Viaud. Localized intracaudate dopamine D2 receptor activation during the post-training period improves memory for visual or olfactory conditioned emotional responses in rats. Behav. Neural Biol., 1991 55: 255-269, 1991.

69. Whishaw, I.Q. and Auer, R.N. Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat. Psychopharmacology.(Berl)., 1989, 98:500-507.

70. Wolf M. E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. In Neurobiol., 1998, vol. 54, P.:679-720.

71. Wolf M.E., Xue C. J., Amphetamine-induced glutamate efflux in the rat ventral tegmental area is prevented by MK-801, SCH 23390, and ibotenic acid lesions of the prefrontal cortex., J. Neurochem. Res., 1999, Vol. 73, P.:41259-66.